Clinical Trial Update: Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the combination of gefitinib and celecoxib in patients with refractory non-small cell lung cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CELEBREX (Celecoxib)
• Iressa (gefitinib)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED